Semiconductor diode laser photocoagulation in retinal vascular disease

Ophthalmology. 1990 Nov;97(11):1553-61. doi: 10.1016/s0161-6420(90)32377-1.

Abstract

The authors successfully performed clinical transpupillary retinal photocoagulation in 30 eyes of 26 patients with retinal vascular disease using a gallium-aluminium-arsenide (GaAlAs) diode laser emitting at 805 nm. Retinal photocoagulation was performed at treatment powers of 300 to 1300 mW and exposure durations of 0.2 to 0.5 seconds with a 200-microns diameter treatment spot. Patients treated with both diode and argon green lasers required 4.5 +/- 1.8 times greater mean laser energy with diode compared with argon to create ophthalmoscopically similar lesions. Parallel experimental retinal photocoagulation in Chinchilla rabbits required 3.1 +/- 0.9 times more power to create ophthalmoscopically similar lesions with the diode laser than with the argon laser. Intraoperative subretinal hemorrhage occurred rarely in patients with an incidence of 4 (0.44%) of 9021 treatment spots. Patients complained of moderate-to-marked pain in 10 (43%) of 23 treatments initiated under topical anesthesia. A transpupillary diode laser may be used clinically to perform therapeutic retinal photocoagulation.

Publication types

  • Clinical Trial
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Argon
  • Female
  • Fluorescein Angiography
  • Fundus Oculi
  • Humans
  • Lasers*
  • Light Coagulation / adverse effects
  • Light Coagulation / instrumentation*
  • Male
  • Middle Aged
  • Prognosis
  • Rabbits
  • Retinal Diseases / surgery
  • Retinal Vessels / surgery*
  • Semiconductors*
  • Visual Acuity

Substances

  • Argon